The results of 39 large varieties collection were executed

1 Shandong first round of drug collection results officially implemented recently, Shandong Medical Insurance Bureau issued "on the implementation of Shandong Province's first batch of drug centralized band procurement results of the notice" clearly, from February 1, Shandong Province, the relevant medical institutions in accordance with the selected price to sell the selected drugs to patients, the implementation of the first batch of drug centralized band procurement results.
according to Cypress Blue combing, Shandong's first round of drug collection across a wide range of time - as early as August 2, 2019, Shandong Province issued relevant opinions to carry out provincial volume procurement.
Then, on April 23, 2020, 40 products began to be reported, and on September 17, 2020, Shandong Province issued a centralized purchase document for pharmaceuticals, followed by an enterprise declaration of product base library information, publicity expert audit results, public declaration information, the first round of simulated quotations, The second round of simulation quotations;
results released by Shandong Province on January 22nd, a total of 39 large varieties of enterprises were selected, involving 157 product rules.
although the time span is long, many processes, but due to the variety involved, the market size, Shandong's first round of mining industry has been highly concerned.
with the results of the election from today officially began to land, 39 varieties in Shandong Province market conditions will open a new round of shuffle.
2 are commonly used drugs, involving the market or more than 5 billion according to cypress blue combing, aspirin, nitrobenzene, mettorol, fluorocarbon, omeprazole, reberazole, compound glyphosate, lansolatone, left ammonia chloride equal common varieties are in Shandong's range - of which 27 injection types, 13 oral dosage forms.
since the main use terminal of injections is a public medical institution, with the landing of the results of the selection, the re-establishment effect on the share of the corresponding injections in the market in public hospitals is more obvious.
Shandong Province's first round of collection, both covering cardiovascular drugs, but also including tumors, digestive systems and other diseases in the field of drug use, involving a market share of 5 billion yuan - so far, a single tissue with the largest number of drug procurement varieties, involving the largest amount of provinces.
According to the official collection results of Shandong Province, there are about 70 pharmaceutical companies selected, involving China Resources Shuanghe, Shanghai Xinyi, Yiling Pharmaceuticals, Jiangsu Hengrui, Zhengda Tianqing, Guo Pharmaceutical Group, Chenxin Pharmaceuticals, Yuanda Pharmaceuticals, Hangzhou Central and Eastern China, Shandong Luoxin Pharmaceuticals, Green Leaf Pharmaceuticals, Shi Shisi Pharmaceuticals, Qilu Pharmaceuticals, Jiangsu Haosen and other well-known pharmaceutical companies, covering 157 product regulations.
According to industry insiders, the average decline in Shandong collection reached more than 50%, there are nearly ten product standards fell by 90%, Shandong Yuxin Pharmaceuticals injection with Lansolaazole injection sterile powder 30mg / bottle fell the most, up to 98.58 percent.
the notice, all public medical institutions and military medical institutions stationed in Lu province in Shandong Province participated in the results of the implementation of the selection, and the remaining medical institutions and retail pharmacies encouraged active participation.
3 Medical institutions began to stock procurement, priority use notice requirements, in accordance with the first round of collection of 39 drugs selected results and Shandong Province collection documents determined the agreed procurement volume allocation rules, the provincial medical insurance bureau to measure the medical institutions in the selection of drugs agreed to the allocation of the amount of procurement ratio, all places to medical institutions reported the drug demand as the base, by reference to the distribution ratio of the first year of the relevant medical institutions to determine the first year of the agreed procurement of drugs.
In order to ensure the use of the selected drugs, Shandong Medical Insurance Bureau's notice requirements - the relevant departments and medical institutions may not limit the reasonable use and supply of the selected drugs on the grounds of cost control, drug proportion, medical institutions, such as the quantity requirements of the drug regulations;
it is worth noting that, in view of the results of the first round of drug collection, Shandong Province began to use the medical insurance payment standards to guide the use of selected and non-selected drugs.
Clear payment criteria, the selected drugs in the medical insurance catalogue to the selected price as the standard for medical insurance payment, the price is lower than or equal to the selected price of the same evaluation group of non-selected drugs, the actual price as the payment standard, the price is higher than the selected price of the same evaluation group of non-selected drugs, the co-ordination areas will be the first out-of-the-way ratio of individual health insurance increased by 10 percentage points.
January 28, the State Council issued the Opinions on Promoting the Normal institutionalization of drug centralized belt procurement, which once again called for coordination between the selected price and the medical insurance payment standard.
" to the health insurance catalog of centralized with the purchase of drugs, based on the selected price to determine the standard of payment for health insurance.
the same standard of medical insurance payment for the original research drugs under the generic name, the evaluation of the generic drugs, the evaluation of generic drugs.
for generic drugs that have not passed the conformity evaluation, the standard of payment for health insurance shall not be higher than for drugs that have passed the conformity evaluation under the generic name".
is not difficult to see, with the collection at the national, inter-provincial and provincial levels, the various safeguards and supporting measures are gradually followed up.
the same time, the market situation between the selected and non-Chinese drug companies will usher in a more disparity.
: Shandong Province drug centralized band procurement results